1
|
Ben Ayed A, Akrout I, Albert Q, Greff S, Simmler C, Armengaud J, Kielbasa M, Turbé-Doan A, Chaduli D, Navarro D, Bertrand E, Faulds CB, Chamkha M, Maalej A, Zouari-Mechichi H, Sciara G, Mechichi T, Record E. Biotransformation of the Fluoroquinolone, Levofloxacin, by the White-Rot Fungus Coriolopsis gallica. J Fungi (Basel) 2022; 8:jof8090965. [PMID: 36135690 PMCID: PMC9506349 DOI: 10.3390/jof8090965] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2022] [Revised: 09/08/2022] [Accepted: 09/12/2022] [Indexed: 11/25/2022] Open
Abstract
The wastewater from hospitals, pharmaceutical industries and more generally human and animal dejections leads to environmental releases of antibiotics that cause severe problems for all living organisms. The aim of this study was to investigate the capacity of three fungal strains to biotransform the fluoroquinolone levofloxacin. The degradation processes were analyzed in solid and liquid media. Among the three fungal strains tested, Coriolopsis gallica strain CLBE55 (BRFM 3473) showed the highest removal efficiency, with a 15% decrease in antibiogram zone of inhibition for Escherichia coli cultured in solid medium and 25% degradation of the antibiotic in liquid medium based on high-performance liquid chromatography (HPLC). Proteomic analysis suggested that laccases and dye-decolorizing peroxidases such as extracellular enzymes could be involved in levofloxacin degradation, with a putative major role for laccases. Degradation products were proposed based on mass spectrometry analysis, and annotation suggested that the main product of biotransformation of levofloxacin by Coriolopsis gallica is an N-oxidized derivative.
Collapse
Affiliation(s)
- Amal Ben Ayed
- Laboratoire de Biochimie et de Genie Enzymatique des Lipases, Ecole Nationale d’Ingenieurs de Sfax, Universite de Sfax, BP 1173, Sfax 3038, Tunisia
- UMR1163, Biodiversite et Biotechnologie Fongiques, Aix-Marseille Universite, INRAE, 13288 Marseille, France
- Correspondence: (A.B.A.); (E.R.)
| | - Imen Akrout
- Laboratoire de Biochimie et de Genie Enzymatique des Lipases, Ecole Nationale d’Ingenieurs de Sfax, Universite de Sfax, BP 1173, Sfax 3038, Tunisia
- UMR1163, Biodiversite et Biotechnologie Fongiques, Aix-Marseille Universite, INRAE, 13288 Marseille, France
| | - Quentin Albert
- UMR1163, Biodiversite et Biotechnologie Fongiques, Aix-Marseille Universite, INRAE, 13288 Marseille, France
- CIRM-CF, INRAE, Aix-Marseille Universite, UMR1163, 13288 Marseille, France
| | - Stéphane Greff
- IMBE, UMR 7263, CNRS, IRD, Aix Marseille Universite, Avignon Universite, Station Marine d’Endoume, Rue de la Batterie des Lions, 13007 Marseille, France
| | - Charlotte Simmler
- IMBE, UMR 7263, CNRS, IRD, Aix Marseille Universite, Avignon Universite, Station Marine d’Endoume, Rue de la Batterie des Lions, 13007 Marseille, France
| | - Jean Armengaud
- Departement Medicaments et Technologies pour la Sante, CEA, INRAE, SPI, Universite Paris-Saclay, 30200 Bagnols-sur-Ceze, France
| | - Mélodie Kielbasa
- Departement Medicaments et Technologies pour la Sante, CEA, INRAE, SPI, Universite Paris-Saclay, 30200 Bagnols-sur-Ceze, France
| | - Annick Turbé-Doan
- UMR1163, Biodiversite et Biotechnologie Fongiques, Aix-Marseille Universite, INRAE, 13288 Marseille, France
| | - Delphine Chaduli
- UMR1163, Biodiversite et Biotechnologie Fongiques, Aix-Marseille Universite, INRAE, 13288 Marseille, France
- CIRM-CF, INRAE, Aix-Marseille Universite, UMR1163, 13288 Marseille, France
| | - David Navarro
- UMR1163, Biodiversite et Biotechnologie Fongiques, Aix-Marseille Universite, INRAE, 13288 Marseille, France
- CIRM-CF, INRAE, Aix-Marseille Universite, UMR1163, 13288 Marseille, France
| | - Emmanuel Bertrand
- UMR1163, Biodiversite et Biotechnologie Fongiques, Aix-Marseille Universite, INRAE, 13288 Marseille, France
| | - Craig B. Faulds
- UMR1163, Biodiversite et Biotechnologie Fongiques, Aix-Marseille Universite, INRAE, 13288 Marseille, France
| | - Mohamed Chamkha
- Laboratoire des Bioprocedes Environnementaux, Centre de Biotechnologie de Sfax, Universite de Sfax, BP 1177, Sfax 3063, Tunisia
| | - Amina Maalej
- Laboratoire des Bioprocedes Environnementaux, Centre de Biotechnologie de Sfax, Universite de Sfax, BP 1177, Sfax 3063, Tunisia
| | - Héla Zouari-Mechichi
- Laboratoire de Biochimie et de Genie Enzymatique des Lipases, Ecole Nationale d’Ingenieurs de Sfax, Universite de Sfax, BP 1173, Sfax 3038, Tunisia
| | - Giuliano Sciara
- UMR1163, Biodiversite et Biotechnologie Fongiques, Aix-Marseille Universite, INRAE, 13288 Marseille, France
| | - Tahar Mechichi
- Laboratoire de Biochimie et de Genie Enzymatique des Lipases, Ecole Nationale d’Ingenieurs de Sfax, Universite de Sfax, BP 1173, Sfax 3038, Tunisia
| | - Eric Record
- UMR1163, Biodiversite et Biotechnologie Fongiques, Aix-Marseille Universite, INRAE, 13288 Marseille, France
- Correspondence: (A.B.A.); (E.R.)
| |
Collapse
|
2
|
Hassani M, Tahghighi A, Rohani M, Hekmati M, Ahmadian M, Ahmadvand H. Robust antibacterial activity of functionalized carbon nanotube- levofloxacine conjugate based on in vitro and in vivo studies. Sci Rep 2022; 12:10064. [PMID: 35710710 PMCID: PMC9203521 DOI: 10.1038/s41598-022-14206-w] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2021] [Accepted: 06/02/2022] [Indexed: 01/28/2023] Open
Abstract
A new nano-antibiotic was synthesized from the conjugation of multi-walled carbon nanotubes with levofloxacin (MWCNT-LVX) through covalent grafting of drug with surface-modified carbon nanotubes in order to achieve an effective, safe, fast-acting nano-drug with the minimal side effects. This study is the first report on the evaluation of in vitro cell viability and antibacterial activity of nano-antibiotic along in addition to the in vivo antibacterial activity in a burn wound model. The drug-loading and release profile at different pH levels was determined using an ultraviolet–visible spectrometer. MWCNT-LVX was synthesized by a simple, reproducible and cost-effective method for the first time and characterized using various techniques, such as scanning electron microscope, transmission electron microscopy, and Brunauer–Emmett–Teller analysis, and so forth. The noncytotoxic nano-antibiotic showed more satisfactory in vitro antibacterial activity against Staphylococcus aureus compared to Pseudomona aeruginosa. The novel synthetic nano-drug possessed high loading capacity and pH-sensitive release profile; resultantly, it exhibited very potent bactericidal activity in a mouse S. aureus wound infection model compared to LVX. Based on the results, the antibacterial properties of the drug enhanced after conjugating with surface-modified MWCNTs. The nano-antibiotic has great industrialization potential for the simple route of synthesis, no toxicity, proper drug loading and release, low effective dose, and strong activity against wound infections. In virtue of unique properties, MWCNTs can serve as a controlled release and delivery system for drugs. The easy penetration to biological membranes and barriers can also increase the drug delivery at lower doses compared to the main drug alone, which can lead to the reduction of its side effects. Hence, MWCNTs can be considered a promising nano-carrier of LVX in the treatment of skin infections.
Collapse
Affiliation(s)
- Marzieh Hassani
- Medicinal Chemistry Laboratory, Clinical Research Department, Pasteur Institute of Iran, Tehran, Iran.,Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
| | - Azar Tahghighi
- Medicinal Chemistry Laboratory, Clinical Research Department, Pasteur Institute of Iran, Tehran, Iran.
| | - Mahdi Rohani
- Department of Microbiology, Pasteur Institute of Iran, Tehran, Iran
| | - Malak Hekmati
- Department of Organic Chemistry, Faculty of Pharmaceutical Chemistry, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
| | - Maryam Ahmadian
- Department of Biostatistics, School of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Hassan Ahmadvand
- Department of Biochemistry, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
| |
Collapse
|
3
|
Corduas F, Mathew E, McGlynn R, Mariotti D, Lamprou DA, Mancuso E. Melt-extrusion 3D printing of resorbable levofloxacin-loaded meshes: Emerging strategy for urogynaecological applications. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2021; 131:112523. [PMID: 34857302 DOI: 10.1016/j.msec.2021.112523] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/21/2021] [Revised: 09/28/2021] [Accepted: 10/23/2021] [Indexed: 12/16/2022]
Abstract
Current surgical strategies for the treatment of pelvic floor dysfunctions involve the placement of a polypropylene mesh into the pelvic cavity. However, polypropylene meshes have proven to have inadequate mechanical properties and have been associated to the arising of severe complications, such as infections. Furthermore, currently employed manufacturing strategies are unable to produce compliant and customisable devices. In this work, polycaprolactone has been used to produce resorbable levofloxacin-loaded meshes in two different designs (90° and 45°) via melt-extrusion 3D printing. Drug-loaded meshes were produced using a levofloxacin concentration of 0.5% w/w. Drug loaded meshes were successfully produced with highly reproducible mechanical and physico-chemical properties. Tensile test results showed that drug-loaded 45° meshes possessed a mechanical behaviour close to that of the vaginal tissue (E ≃ 8.32 ± 1.85 MPa), even after 4 weeks of accelerated degradation. Meshes released 80% of the loaded levofloxacin in the first 3 days and were capable of producing an inhibitory effect against S. Aureus and E. coli bacterial strains with an inhibition zone equal to 12.8 ± 0.45 mm and 15.8 ± 0.45 mm respectively. Thus, the strategy adopted in this work holds great promise for the manufacturing of custom-made surgical meshes with antibacterial properties.
Collapse
Affiliation(s)
- Francesca Corduas
- Nanotechnology and Integrated Bio-Engineering Centre (NIBEC), Ulster University, Jordanstown Campus -, Newtownabbey BT37 0QB, UK; School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK
| | - Essyrose Mathew
- School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK
| | - Ruairi McGlynn
- Nanotechnology and Integrated Bio-Engineering Centre (NIBEC), Ulster University, Jordanstown Campus -, Newtownabbey BT37 0QB, UK
| | - Davide Mariotti
- Nanotechnology and Integrated Bio-Engineering Centre (NIBEC), Ulster University, Jordanstown Campus -, Newtownabbey BT37 0QB, UK
| | | | - Elena Mancuso
- Nanotechnology and Integrated Bio-Engineering Centre (NIBEC), Ulster University, Jordanstown Campus -, Newtownabbey BT37 0QB, UK.
| |
Collapse
|
4
|
Rowan-Nash AD, Araos R, D'Agata EMC, Belenky P. Antimicrobial Resistance Gene Prevalence in a Population of Patients with Advanced Dementia Is Related to Specific Pathobionts. iScience 2020; 23:100905. [PMID: 32106056 PMCID: PMC7044522 DOI: 10.1016/j.isci.2020.100905] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2019] [Revised: 01/10/2020] [Accepted: 02/06/2020] [Indexed: 12/12/2022] Open
Abstract
Long-term care facilities are significant reservoirs of antimicrobial-resistant organisms, and patients with advanced dementia are particularly vulnerable to multidrug-resistant organism (MDRO) acquisition and antimicrobial overuse. In this study, we longitudinally examined a group of patients with advanced dementia using metagenomic sequencing. We found significant inter- and intra-subject heterogeneity in microbiota composition, suggesting temporal instability. We also observed a link between the antimicrobial resistance gene density in a sample and the relative abundances of several pathobionts, particularly Escherichia coli, Proteus mirabilis, and Enterococcus faecalis, and used this relationship to predict resistance gene density in samples from additional subjects. Furthermore, we used metagenomic assembly to demonstrate that these pathobionts had higher resistance gene content than many gut commensals. Given the frequency and abundances at which these pathobionts were found in this population and the underlying vulnerability to MDRO of patients with advanced dementia, attention to microbial blooms of these species may be warranted.
Collapse
Affiliation(s)
- Aislinn D Rowan-Nash
- Department of Molecular Microbiology and Immunology, Brown University, Providence, RI 02912, USA
| | - Rafael Araos
- Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina Clinica Alemana Universidad del Desarrollo, Santiago, Chile; Millenium Nucleus for Collaborative Research on Bacterial Resistance (MICROB-R), Santiago, Chile; Advanced Center for Chronic Diseases (ACCDiS), Facultad de Medicina Clinica Alemana Universidad del Desarrollo, Santiago, Chile
| | - Erika M C D'Agata
- Infectious Diseases Division, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI 02903, USA
| | - Peter Belenky
- Department of Molecular Microbiology and Immunology, Brown University, Providence, RI 02912, USA.
| |
Collapse
|
6
|
Denes E, Prouzergue J, Ducroix-Roubertou S, Aupetit C, Weinbreck P. Antibiotic prescription by general practitioners for urinary tract infections in outpatients. Eur J Clin Microbiol Infect Dis 2012; 31:3079-83. [PMID: 22722765 DOI: 10.1007/s10096-012-1668-9] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2012] [Accepted: 05/28/2012] [Indexed: 11/29/2022]
Abstract
In July 2008, in France, guidelines for antibiotic prescriptions for urinary tract infections (UTIs) were amended. As general practitioners (GPs) treat numerous UTIs, we wanted to evaluate whether they followed these guidelines. In order to do this, we performed a prospective study. The point of call was urinalyses. Using this selection method together with criteria diagnostic for urinalysis, we confirmed that patients presented a UTI. Each GP was contacted. Prescriptions were analysed and compared to the 2008 French guidelines for UTIs. Our study included 185 urinalyses. UTIs diagnosed by GPs were as follows: acute cystitis: 72.4 %, prostatitis: 13.5 %, nephritis: 8.7 % and asymptomatic bacteriuria: 5.4 %. The principal antibiotics used were: quinolone (59.5 %), furan (17.8 %) and cotrimoxazole (6.5 %). Only 20 % of the prescriptions were compliant with the guidelines. The correct antibiotic but not the dose or the duration of prescription was selected in 8.1 % of the prescriptions. For cystitis, inappropriate prescription was associated with an extra cost of 694 <euro>, namely, 7.4 <euro> per treatment. GP prescriptions for UTIs do not follow the guidelines. Even if GPs assert that they are aware of the emergence of resistant strains, it seems that they do not take into account the objective of quinolone restriction, which was one of the backbones of these guidelines.
Collapse
Affiliation(s)
- E Denes
- Infectious Diseases Department, Limoges Teaching Hospital, Limoges, France.
| | | | | | | | | |
Collapse
|